



# Tamsulosin Shortage

TABLE 1: Tamsulosin hydrochloride products marketed in Canada<sup>a</sup>

Product	Strength	DIN	Manufacturer
Apo-Tamsulosin CR	0.4 mg CR tablet	02362406	Apotex Inc.
Flomax CR	0.4 mg CR tablet	02270102	Boehringer Ingelheim (Canada) Ltd.
JAMP-Tamsulosin	0.4 mg SR capsule	02352419	JAMP Pharma Corporation
Tamsulosin CR	0.4 mg CR tablet	02413612	Pro Doc Ltée
Sandoz Tamsulosin	0.4 mg SR capsule	02319217	Sandoz Canada Incorporated
Sandoz Tamsulosin CR	0.4 mg CR tablet	02340208	Sandoz Canada Incorporated
Tamsulosin CR	0.4 mg CR tablet	02427117	Sanis Health Inc.
Tamsulosin CR	0.4 mg CR tablet	02429667	Sivem Pharmaceuticals ULC
Teva-Tamsulosin CR	0.4 mg CR tablet	02368242	Teva Canada Limited

<sup>a</sup>Also available in combination products with dutasteride. Consult Health Canada's Drug Product Database at [www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php](http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdon/index-eng.php).

## Health Canada-approved indication of tamsulosin hydrochloride:

- Treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)

## Management Options:

The nonselective (**alfuzosin, doxazosin, terazosin**) and selective (**silodosin, tamsulosin**) alpha<sub>1</sub>-adrenergic receptor antagonists (alpha blockers) and the 5-alpha-reductase inhibitors (**dutasteride, finasteride**) are all useful in improving LUTS.

Although there are differences in the adverse event profiles of the alpha blockers, all 5 have comparable clinical effectiveness. Choice of agent depends upon the side effect profile and on the patient's comorbidities and individual tolerance.

TABLE 2: Drug class: alpha<sub>1</sub>-adrenergic receptor antagonists

Drug	Dosage	Adverse Effects
Alfuzosin	10 mg once daily PO	Dizziness, fatigue, headache, upper respiratory tract infection.
Doxazosin	1-8 mg QHS PO	Orthostatic hypotension, dizziness, headache, asthenia and nasal congestion; syncope.
Silodosin	8 mg once daily PO (4 mg once daily PO if ClCr 30-50 mL/min)	Diarrhea, dizziness, headache, nasal congestion, orthostatic hypotension; decreased ejaculate volume.
Tamsulosin	0.4 mg once daily PO	Dizziness, retrograde ejaculation.
Terazosin	1-10 mg QHS PO	Orthostatic hypotension, dizziness, headache, asthenia and nasal congestion; syncope.

TABLE 3: Drug class: 5-alpha-reductase inhibitors

Drug	Dosage	Adverse Effects
Dutasteride	0.5 mg once daily PO	Sexual dysfunction.
Finasteride	5 mg once daily PO	Sexual dysfunction; risk of serious muscle-related adverse effects (rare); risk of suicidal ideation (rare).

TABLE 4: Alfuzosin products marketed in Canada

Product	Strength	DIN	Manufacturer
Apo-Alfuzosin	10 mg tablet	02315866	Apotex Inc.
Auro-Alfuzosin	10 mg tablet	02443201	Auro Pharma Inc.
Sandoz-Alfuzosin	10 mg tablet	02304678	Sandoz Canada Incorporated
Alfuzosin	10 mg tablet	02519844	Sanis Health Inc.
Xatral	10 mg tablet	02245565	Sanofi-Aventis Canada Inc.
Alfuzosin	10 mg tablet	02447576	Sivem Pharmaceuticals ULC

TABLE 5: Doxazosin products marketed in Canada

Product	Strength	DIN	Manufacturer
Apo-Doxazosin	1 mg tablet	02240588	Apotex Inc.
	2 mg tablet	02240589	
	4 mg tablet	02240590	
JAMP-Doxazosin	1 mg tablet	02489937	JAMP Pharma Corporation
	2 mg tablet	02489945	
	4 mg tablet	02489953	
Teva-Doxazosin	1 mg tablet	02242728	Teva Canada Limited
	2 mg tablet	02242729	
	4 mg tablet	02242730	

TABLE 6: Silodosin products marketed in Canada

Product	Strength	DIN	Manufacturer
Auro-Silodosin	4 mg tablet	02478501	Auro Pharma Inc.
	8 mg tablet	02478528	
pms-Silodosin	4 mg tablet	02517779	Pharmascience Inc.
	8 mg tablet	02517787	
Sandoz-Silodosin	4 mg tablet	02475421	Sandoz Canada Incorporated
	8 mg tablet	02475448	

TABLE 7: Terazosin products marketed in Canada

Product	Strength	DIN	Manufacturer
Apo-Terazosin	1 mg tablet	02234502	Apotex Inc.
	2 mg tablet	02234503	
	5 mg tablet	02234504	
	10 mg tablet	02234505	
pms-Terazosin	1 mg tablet	02243518	Pharmascience Inc.
	2 mg tablet	02243519	
	5 mg tablet	02243520	
	10 mg tablet	02243521	
Teva-Terazosin	5 mg tablet	02230807	Teva Canada Limited

TABLE 8: Dutasteride products marketed in Canada

Product	Strength	DIN	Manufacturer
Apo-Dutasteride	0.5 mg capsule	02404206	Apotex Inc.
Auro-Dutasteride	0.5 mg capsule	02469308	Auro Pharma Inc.
Med-Dutasteride	0.5 mg capsule	02416298	Generic Medical Partners Inc.
Avodart	0.5 mg capsule	02247813	GlaxoSmithKline Inc.
JAMP-Dutasteride	0.5 mg capsule	02484870	JAMP Pharma Corporation
Riva-Dutasteride	0.5 mg capsule	02427753	Laboratoire Riva Inc.
Mint-Dutasteride	0.5 mg capsule	02428873	Mint Pharmaceuticals Inc.
NRA-Dutasteride	0.5 mg capsule	02490587	Nora Pharma Inc.
Dutasteride	0.5 mg capsule	02421712	Pro Doc Ltée
Dutasteride	0.5 mg capsule	02443058	Sanis Health Inc.
Dutasteride	0.5 mg capsule	02429012	Sivem Pharmaceuticals ULC
ACT-Dutasteride	0.5 mg capsule	02412691	Teva Canada Limited
Teva-Dutasteride	0.5 mg capsule	02408287	Teva Canada Limited

TABLE 9: Finasteride 5 mg products marketed in Canada

Product	Strength	DIN	Manufacturer
ACH-Finasteride	5 mg tablet	02355043	Accord Healthcare Inc.
AG-Finasteride	5 mg tablet	02374404	Angita Pharma Inc.
Apo-Finasteride	5 mg tablet	02365383	Apotex Inc.
Auro-Finasteride	5 mg tablet	02405814	Auro Pharma Inc.
Bio-Finasteride	5 mg tablet	02527847	Biomed Pharma
JAMP-Finasteride	5 mg tablet	02357224	JAMP Pharma Corporation
Riva-Finasteride	5 mg tablet	02455013	Laboratoire Riva Inc.
M-finasteride	5 mg tablet	02522489	Mantra Pharma Inc.
Mint-Finasteride	5 mg tablet	02389878	Mint Pharmaceuticals Inc.
Proscar	5 mg tablet	02010909	Organon Canada Inc.
pms-Finasteride	5 mg tablet	02310112	Pharmascience Inc.
Finasteride	5 mg tablet	02350270	Pro Doc Ltée
Sandoz-Finasteride	5 mg tablet	02322579	Sandoz Canada Incorporated
Finasteride	5 mg tablet	02445077	Sanis Health Inc.
Finasteride	5 mg tablet	02447541	Sivem Pharmaceuticals ULC
Teva-Finasteride	5 mg tablet	02348500	Teva Canada Limited

### References

CPS: Drug Information. Alpha<sub>1</sub>-adrenergic receptor antagonists [drug monograph]. Canadian Pharmacists Association; 2015. Available from: <https://cps.pharmacists.ca>. Subscription required. Accessed January 30, 2024.

Health Canada. Drug product database online query [internet]. Ottawa: Health Canada; 2023. Available from: <https://health-products.canada.ca/dpd-bdpp>. Accessed January 30, 2024.

Norman RW. Lower urinary tract symptoms and benign prostatic hyperplasia [internet]. November 24, 2023. Available from: <https://cps.pharmacists.ca>. Subscription required. Accessed January 30, 2024.